Q-omics provides the consensus-scored RSPH4A profile across patient tissues and cancer cell-line models. RSPH4A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RSPH4A is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RSPH4A RNA expression shows 18,947 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where RSPH4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPH4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPH4A survival associations across molecular data types. RSPH4A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPH4A RNA expression–survival associations across cancer types. High RSPH4A expression shows unfavorable associations in LGG and KIRC, but favorable associations in BRCA, HNSC, PAAD and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RSPH4A RNA expression.
This table summarizes RSPH4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RSPH4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPH4A shows lower tumor expression in KICH, KIRC, LUAD, THCA and LUSC and higher tumor expression in PRAD. The KICH box plot shows higher RSPH4A RNA expression in normal versus tumor tissue (log2 FC = −1.640, t-test p < 0.001).
This table shows molecular features associated with RSPH4A in patient tissues and cancer cell lines. In patient samples, RSPH4A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPH4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
